
Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema If the FDA approves Lonvoguran Ziclumeran, lonvo-z, for Hereditary Angioedema for marketing before X 1, Y then the market resolves to Yes. Early close condition: This market will close and expire early if the event occurs. This market will close and expire early if the event occurs.
65%
$0.00
3

65%
$0.00
3
3 markets tracked
No data available
| Market | Price |
|---|---|
When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before 2028) | 65% |
When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before October 2027) | 45% |
When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before July 2027) | 31% |